UTime Ltd
WTO

$0.5259

3.08%

Market Cap: $9.49M

About: UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; and Do, as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.

Employees: 172

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

118% more capital invested

Capital invested by funds: $22.3K [Q1] → $48.4K (+$26.2K) [Q2]

0.16% less ownership

Funds ownership: 0.54% [Q1] → 0.39% (-0.16%) [Q2]

25% less funds holding

Funds holding: 4 [Q1] → 3 (-1) [Q2]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for WTO.

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about WTO published over the past 30 days

UTime Limited Announces Pricing of $5 Million Registered Direct Offering

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- UTime Limited (“UTime” or the “Company”) (Nasdaq: WTO), a mobile device manufacturing company committed to providing cost effective products and solutions to consumers globally and helping low-income individuals from established and emerging markets today announced that it has entered into a securities purchase agreement with certain accredited investor to sell $5 million of its ordinary shares in a registered direct offering.

UTime Limited Announces Pricing of $5 Million Registered Direct Offering

UTime Limited Announces 1-For-25 Reverse Share Split

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- UTime Limited (“UTime” or the “Company”) (Nasdaq: WTO), a mobile device manufacturing company committed to providing cost effective products and solutions to consumers globally and helping low-income individuals from established and emerging markets today announced that it will effect a reverse share split of its outstanding ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), at a ratio of 1-for-25, to be effective on or around the open of trading on September 11, 2024.

UTime Limited Announces 1-For-25 Reverse Share Split

Remarkable Announcement on Significant Fluctuation of the UTime's Share Price

SHENZHEN, China , Aug. 29, 2024 /PRNewswire/ -- Dear Investors, Analysts and Media: Recently, UTime Ltd ("UTime") has experienced a period of unusual share price volatility in the capital markets. As a responsible company, we understand the concerns of market participants about such situations and believe that it is necessary to provide the public with transparent and formalized information in this regard.

Remarkable Announcement on Significant Fluctuation of the UTime's Share Price

UTime Initiates Financial and Legal Due Diligence on Bowen Therapeutics

SHENZHEN, China , Aug. 29, 2024 /PRNewswire/ -- UTime Limited (NASDAQ: WTO ) ("UTime" or the "Company"), which continues to build on its strengths in the global healthcare sector, has announced that it has commenced a comprehensive financial and legal due diligence on Bowen Therapeutics Inc ("Bowen Therapeutics"), which it intends to acquire. The move marks an important step in UTime's expansion of its presence in the field of innovative medical products, with the aim of strengthening its market position and advancing the future of medical technology.

UTime Initiates Financial and Legal Due Diligence on Bowen Therapeutics

UTime Signs NDA to Acquire Monkeypox Vaccine Maker Bowen Therapeutics Inc and Supports Completion of FDA Registration of Related Vaccines

SHENZHEN, China , Aug. 28, 2024 /PRNewswire/ -- UTime Limited (NASDAQ: WTO) ("UTime" or the "Company") has officially announced the signing of a non-disclosure agreement (the "NDA") with Bowen Therapeutics Inc ("Bowen Therapeutics") for the acquisition of the Bowen Therapeutics laboratory at UMASS Medical School. This strategic move not only marks UTime's in-depth expansion in the global vaccine market, but also provides strong support for the registration of the relevant vaccine through the U.S. Food and Drug Administration (the "FDA").

UTime Signs NDA to Acquire Monkeypox Vaccine Maker Bowen Therapeutics Inc and Supports Completion of FDA Registration of Related Vaccines

About Circul VS: A Core Continuous Blood Pressure Measurement Technology System Developed in Partnership with Dr. Ehud Baron

SHENZHEN, China , Aug. 26, 2024 /PRNewswire/ -- UTime Limited (NASDAQ: WTO) ("UTime" or the "Company") is excited to announce its collaboration on Circul VS, a core continuous blood pressure measurement technology system developed in partnership with strategic partner, Dr. Ehud Baron. Designed to offer patients an accurate and user-friendly continuous blood pressure monitoring solution, Circul VS facilitates early detection and long-term management, helping to reduce the risks associated with cardiovascular and cerebrovascular conditions.

About Circul VS: A Core Continuous Blood Pressure Measurement Technology System Developed in Partnership with Dr. Ehud Baron

UTime Limited to Participate in International Medical Fairs and Medical Conferences

SHENZHEN, China , Aug. 23, 2024 /PRNewswire/ -- UTime Limited (NASDAQ: WTO) ("UTime" or the "Company") is pleased to announce its plans to participate in a series of internationally recognized medical fairs and medical conferences. These forthcoming events will provide a valuable opportunity for UTime to showcase its latest achievements in medical devices and solutions and to enhance its communication and partnerships within the global medical industry.

UTime Limited to Participate in International Medical Fairs and Medical Conferences

UTime Limited Announces Ambitious AI Health Strategy and Strategic Collaboration

SHENZHEN, China , Aug. 21, 2024 /PRNewswire/ -- UTime Limited (NASDAQ: WTO) ("UTime" or the "Company") is pleased to announce its ambitious strategy for advancing AI-driven health solutions. Recognizing the growing value and potential of smart health technologies, UTime is committing significant investments to expand its smart medical wearable products business.

UTime Limited Announces Ambitious AI Health Strategy and Strategic Collaboration

UTime Limited Partners with Dr. Ehud Baron to Pioneer AI-Driven Health Solutions

SHENZHEN, China , Aug. 19, 2024 /PRNewswire/ -- UTime Limited (NASDAQ: WTO) ("UTime" or the "Company") is pleased to announce a Memorandum of Understanding ("MOU") with XCardio, a Japanese company owned by Dr. Ehud Baron, a leader in medical technology innovation. This partnership focuses on the joint development of state-of-the-art continuous blood pressure monitoring devices, BPWatch, aimed at advancing cardiovascular disease management.

UTime Limited Partners with Dr. Ehud Baron to Pioneer AI-Driven Health Solutions

See News Rankings